Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways

Experimental Cell Research

Volumn 315, Issue 12, 2009, Pages 2022-2032

  Matsuoka, Hiroshi ^a,b   Tsubaki, Masanobu ^a   Yamazoe, Yuzuru ^c   Ogaki, Mitsuhiko ^d   Satou, Takao ^e   Itoh, Tatsuki ^e   Kusunoki, Takashi ^f   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^c KINDAI UNIVERSITY HOSPITAL   (Japan)

^d Department of Pharmacy   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Invasion; Melanoma; Metastasis; Protein kinase C; Tamoxifen

Indexed keywords

COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; IN VITRO STUDY; LUNG METASTASIS; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 67349246432     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.04.009     Document Type: Article

References (35)

1. Woodhouse E.C., Chuaqui R.F., and Liotta L.A. General mechanisms of metastasis. Cancer 80 (1997) 1529-1537
2. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9 (1990) 289-303
3. Hofmann U.B., Westphal J.R., Van Muijen G.N., and Ruiter D.J. Matrix metalloproteinases in human melanoma. J. Invest. Dermatol. 115 (2000) 337-344
4. Hendrix M.J., Seftor E.A., Kirschmann D.A., Quaranta V., and Seftor R.E. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann. N.Y. Acad. Sci. 995 (2003) 151-161
5. Kerkela E., and Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp. Dermatol. 12 (2003) 109-125
6. Eccles S.A., Box G.M., Court W.J., Bone E.A., Thomas W., and Brown P.D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56 (1996) 2815-2822
7. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
8. Azzi A., Boskoboinik D., and Henesey C. The protein kinase C family. Eur. J. Biochem. 208 (1992) 547-557
9. Blobe G.C., Obeid L.M., and Hannun Y.A. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 13 (1994) 411-431
10. Oka M., and Kikkawa U. Protein kinase C in melanoma. Cancer Metastasis Rev. 24 (2005) 287-300
11. Tsubaki M., Matsuoka H., Yamamoto C., Kato C., Ogaki M., Satou T., Itoh T., Kusunoki T., Tanimori Y., and Nishida S. The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2. Clin. Exp. Metastasis 24 (2007) 431-438
12. Goldenberg G.J., and Froese E.K. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vivo. Cancer Res. 42 (1982) 5147-5151
13. Gelmann E.P. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog. J. Natl. Cancer Inst. (Bethesda) 88 (1996) 224-226
14. Luo W., Sharif T.R., Houghton P.J., and Sharif M. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Differ. 8 (1997) 1225-1240
15. Gundimeda U., Chen Z.-H., and Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J. Biol. Chem. 171 (1996) 13504-13514
16. Zhang W., Yamada H., Sakai N., Niikawa S., and Nozawa Y. Enhancement of radiosensitivity by tamoxifen in C6 glioma cells. Neurosurgery 31 (1992) 725-730
17. Zhang W., Law R.E., Hinton D.R., and Couldwell W.T. Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett. 120 (1997) 31-38
18. Szaniawska B., Gawrychowski K., and Janik P. The effect of protein kinase C inhibitors on invasion of human ovary cancer cells. Neoplasma 45 (1998) 7-11
19. Chen J., and Thompson L.U. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Res. Treat. 80 (2003) 163-170
20. Lahn M.M., and Sundell K.L. The role of protein kinase C-alpha (PKC-alpha) in melanoma. Melanoma Res. 2 (2004) 85-89
21. Wu T.T., Hsieh Y.H., Hsieh Y.S., and Liu J.Y. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J. Cell. Biochem. 103 (2008) 9-20
22. Park M.J., Park I.C., Lee H.C., Woo S.H., Lee J.Y., Hong Y.J., Rhee C.H., Lee Y.S., Lee S.H., Shim B.S., Kuroki T., and Hong S.I. Protein kinase C-alpha activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. Int. J. Oncol. 22 (2003) 137-143
23. Hussaini I.M., Trotter C., Zhao Y., Abdel-Fattah R., Amos S., Xiao A., Agi C.U., Redpath G.T., Fang Z., Leung G.K., Lopes M.B., and Laws E.R. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am. J. Pathol. 170 (2007) 356-365
24. Barragan M., Bellosillo B., Campas C., Colomer D., Pons G., and Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 99 (2002) 2969-2976
25. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 253 (2003) 269-285
26. Thant A.A., Nawa A., Kikkawa F., Ichigotani Y., Zhang Y., Sein T.T., Amin A.R., and Hamaguhi M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin. Exp. Metastasis 18 (2000) 423-428
27. Vincenti M.P., White L.A., Schroen D.J., Benbow U., and Brinckerhoff C.E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit. Rev. Eukaryot. Gene Expr. 6 (1996) 391-411
28. Bianchini F., D'Alessio S., Fibbi G., Del Rosso M., and Calorini L. Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9. Oncol. Rep. 15 (2006) 709-714
29. Yeh M.W., Rougier J.P., Park J.W., Duh Q.Y., Wong M., Werb Z., and Clark O.H. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr. Relat. Cancer 13 (2006) 1173-1183
30. Henson E.S., and Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell. Signal. 18 (2006) 2089-2097
31. Liau S.S., Jazag A., and Whang E.E. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 66 (2006) 11613-11622
32. Cole Jr. G.W., Alleva A.M., Zuo J.T., Sehgal S.S., Yeow W.S., Schrump D.S., and Nguyen D.M. Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor U0126. Anticancer Res. 26 (2006) 809-821
33. Sartippour M.R., Pietras R., Marquez-Garban D.C., Chen H.W., Heber D., Henning S.M., Sartippour G., Zhang L., Lu M., Weinberg O., Rao J.Y., and Brooks M.N. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 27 (2006) 2424-2433
34. Conley B.A., Ramsland T.S., Sentz D.L., Wu S., Rosen D.M., Wollman M., and Eiseman J.L. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother. Pharmacol. 43 (1999) 183-197
35. Guo Y., Mazar A.P., Lebrun J.J., and Rabbani S.A. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res. 62 (2002) 4678-4684